These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 29951802)

  • 1. Body mass index and all-cause mortality in heart failure patients with normal and reduced ventricular ejection fraction: a dose-response meta-analysis.
    Zhang J; Begley A; Jackson R; Harrison M; Pellicori P; Clark AL; Cleland JGF
    Clin Res Cardiol; 2019 Feb; 108(2):119-132. PubMed ID: 29951802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BNP and obesity in acute decompensated heart failure with preserved vs. reduced ejection fraction: The Atherosclerosis Risk in Communities Surveillance Study.
    Khalid U; Wruck LM; Quibrera PM; Bozkurt B; Nambi V; Virani SS; Jneid H; Agarwal S; Chang PP; Loehr L; Basra SS; Rosamond W; Ballantyne CM; Deswal A
    Int J Cardiol; 2017 Apr; 233():61-66. PubMed ID: 28185703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence and prognostic impact of non-cardiac co-morbidities in heart failure outpatients with preserved and reduced ejection fraction: a community-based study.
    Iorio A; Senni M; Barbati G; Greene SJ; Poli S; Zambon E; Di Nora C; Cioffi G; Tarantini L; Gavazzi A; Sinagra G; Di Lenarda A
    Eur J Heart Fail; 2018 Sep; 20(9):1257-1266. PubMed ID: 29917301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heart failure with preserved ejection fraction has a better long-term prognosis than heart failure with reduced ejection fraction in old patients in a 5-year follow-up retrospective study.
    Kontogeorgos S; Thunström E; Johansson MC; Fu M
    Int J Cardiol; 2017 Apr; 232():86-92. PubMed ID: 28100428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of hyponatremia among ambulatory patients with heart failure and preserved and reduced ejection fractions.
    Bavishi C; Ather S; Bambhroliya A; Jneid H; Virani SS; Bozkurt B; Deswal A
    Am J Cardiol; 2014 Jun; 113(11):1834-8. PubMed ID: 24837261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recovered heart failure with reduced ejection fraction and outcomes: a prospective study.
    Lupón J; Díez-López C; de Antonio M; Domingo M; Zamora E; Moliner P; González B; Santesmases J; Troya MI; Bayés-Genís A
    Eur J Heart Fail; 2017 Dec; 19(12):1615-1623. PubMed ID: 28387002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of body mass index and prognosis in patients with HFpEF: A dose-response meta-analysis.
    Li S; Zheng Y; Huang Y; He W; Liu X; Zhu W
    Int J Cardiol; 2022 Aug; 361():40-46. PubMed ID: 35568057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute heart failure with mid-range left ventricular ejection fraction: clinical profile, in-hospital management, and short-term outcome.
    Farmakis D; Simitsis P; Bistola V; Triposkiadis F; Ikonomidis I; Katsanos S; Bakosis G; Hatziagelaki E; Lekakis J; Mebazaa A; Parissis J
    Clin Res Cardiol; 2017 May; 106(5):359-368. PubMed ID: 27999929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of elevated heart rate on clinical outcomes in patients with heart failure with reduced and preserved ejection fraction: a report from the CHART-2 Study.
    Takada T; Sakata Y; Miyata S; Takahashi J; Nochioka K; Miura M; Tadaki S; Shimokawa H;
    Eur J Heart Fail; 2014 Mar; 16(3):309-16. PubMed ID: 24464774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between use of β-blockers and outcomes in patients with heart failure and preserved ejection fraction.
    Lund LH; Benson L; Dahlström U; Edner M; Friberg L
    JAMA; 2014 Nov; 312(19):2008-18. PubMed ID: 25399276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tolerability and Feasibility of Beta-Blocker Titration in HFpEF Versus HFrEF: Insights From the CIBIS-ELD Trial.
    Edelmann F; Musial-Bright L; Gelbrich G; Trippel T; Radenovic S; Wachter R; Inkrot S; Loncar G; Tahirovic E; Celic V; Veskovic J; Zdravkovic M; Lainscak M; Apostolović S; Neskovic AN; Pieske B; Düngen HD;
    JACC Heart Fail; 2016 Feb; 4(2):140-149. PubMed ID: 26682793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comprehensive population-based characterization of heart failure with mid-range ejection fraction.
    Koh AS; Tay WT; Teng THK; Vedin O; Benson L; Dahlstrom U; Savarese G; Lam CSP; Lund LH
    Eur J Heart Fail; 2017 Dec; 19(12):1624-1634. PubMed ID: 28948683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heart failure medication dosage and survival in women and men seen at outpatient clinics.
    Bots SH; Onland-Moret NC; Tulevski II; van der Harst P; Cramer MJM; Asselbergs FW; Somsen GA; den Ruijter HM
    Heart; 2021 Nov; 107(21):1748-1755. PubMed ID: 34261736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Body mass index and outcomes in ischaemic versus non-ischaemic heart failure across the spectrum of ejection fraction.
    Gentile F; Sciarrone P; Zamora E; De Antonio M; Santiago E; Domingo M; Aimo A; Giannoni A; Passino C; Codina P; Bayes-Genis A; Lupon J; Emdin M; Vergaro G
    Eur J Prev Cardiol; 2021 Aug; 28(9):948-955. PubMed ID: 34402870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential impact of heart rate and blood pressure on outcome in patients with heart failure with reduced versus preserved left ventricular ejection fraction.
    Maeder MT; Kaye DM
    Int J Cardiol; 2012 Mar; 155(2):249-56. PubMed ID: 21035207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of 5-Year Outcomes After Coronary Artery Bypass Grafting in Heart Failure Patients With Versus Without Preserved Left Ventricular Ejection Fraction (from the CREDO-Kyoto CABG Registry Cohort-2).
    Marui A; Nishiwaki N; Komiya T; Hanyu M; Tanaka S; Kimura T; Sakata R;
    Am J Cardiol; 2015 Aug; 116(4):580-6. PubMed ID: 26092271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry.
    Chioncel O; Lainscak M; Seferovic PM; Anker SD; Crespo-Leiro MG; Harjola VP; Parissis J; Laroche C; Piepoli MF; Fonseca C; Mebazaa A; Lund L; Ambrosio GA; Coats AJ; Ferrari R; Ruschitzka F; Maggioni AP; Filippatos G
    Eur J Heart Fail; 2017 Dec; 19(12):1574-1585. PubMed ID: 28386917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Effects of Statin Use on Mortality in Patients With Heart Failure and Preserved Versus Reduced Left Ventricular Ejection Fraction.
    Lee MS; Duan L; Clare R; Hekimian A; Spencer H; Chen W
    Am J Cardiol; 2018 Aug; 122(3):405-412. PubMed ID: 30201108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparable prognostic impact of BNP levels among HFpEF, Borderline HFpEF and HFrEF: a report from the CHART-2 Study.
    Kasahara S; Sakata Y; Nochioka K; Yamauchi T; Onose T; Tsuji K; Abe R; Oikawa T; Sato M; Aoyanagi H; Miura M; Shiroto T; Takahashi J; Miyata S; Shimokawa H;
    Heart Vessels; 2018 Sep; 33(9):997-1007. PubMed ID: 29569034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial.
    Haass M; Kitzman DW; Anand IS; Miller A; Zile MR; Massie BM; Carson PE
    Circ Heart Fail; 2011 May; 4(3):324-31. PubMed ID: 21350053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.